Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
24-26 June, 2025
Not Confirmed
Not Confirmed
09-11 June, 2025
Annual Outsourcing in ...Annual Outsourcing in CT
Not Confirmed
Not Confirmed
10-11 June, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
24-26 June, 2025
Industry Trade Show
Not Confirmed
09-11 June, 2025
Annual Outsourcing in ...Annual Outsourcing in CT
Industry Trade Show
Not Confirmed
10-11 June, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-roquette-announces-restructuring-post-iff-pharma-buyout-who-fda-advance-regulatory-frameworks
30 May 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/immunogenesis-to-present-imgs-001-phase-1a1b-clinical-study-updates-at-the-2025-american-society-of-clinical-oncology-asco-annual-meeting-302469451.html
06 Mar 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/immunogenesis-doses-first-patient-in-phase-12-clinical-trial-of-imgs-101-in-combination-with-balstilimab-anti-pd-1-and-zalifrelimab-anti-ctla-4-in-relapsed-or-refractory-advanced-prostate-pancreatic-and-hpv--head--neck-t-302393719.html
11 Dec 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/12/11/2995254/0/en/PolyPid-Announces-Research-and-Development-Collaboration-with-ImmunoGenesis-Leveraging-PLEX-Technology-to-Enhance-Cancer-Immunotherapy.html
28 Sep 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/immunogenesis-doses-first-patient-in-phase-1a1b-clinical-trial-of-imgs-001-in-relapsed-or-refractory-advanced-solid-tumors-301941636.html
27 Jun 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/immunogenesis-and-cancer-focus-fund-announce-4-5-million-investment-to-support-first-in-human-trial-of-imgs-001-for-relapsed-or-refractory-advanced-solid-tumors-301863976.html
03 Nov 2022
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/immunogenesis-to-present-pre-clinical-data-from-lead-program-at-society-for-immunotherapy-of-cancer-conference-301666763.html
ABOUT THIS PAGE